Novoheart, AstraZeneca collaborate on human-specific model of HFpEF
Canadian stem cell biotechnology firm Novoheart has partnered with AstraZeneca to develop the human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF). Novoheart said